New Halycyon Radiotherapy System by Varian Introduced in China

The new Halcyon radiotherapy system from Varian features the ProBeam® 360°. It is a new single-room proton therapy system. The new product will be introduced in Wuhan, China  January 12-13 at the China Users Meeting. This story is related to the following:Radiotherapy Systems
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news

Related Links:

ConclusionDespite the dosimetric precision of proton therapy, orbital asymmetry will develop after>40 GyRBE to multiple bones of the orbital rim. These data may be used to guide treatment planning and counsel patients on expected cosmesis.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Penn Medicine Lancaster General Health has started construction of a $48 million proton therapy center. The proton therapy center, part of Lancaster General Health's Ann B. Barshinger Cancer Institute, will be the second site in Pennsylvania to offer the high-tech form of radiation therapy to cancer patients when it opens in the fall of 2021. The first proton therapy center in Pennsylvania opened a t Penn, in a 75,000-square-foot building that is part of the Abramson Cancer Center, in 2010. Penn…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
PALO ALTO, Calif., Oct. 14, 2019 /PRNewswire/ -- Varian (NYSE: VAR) in collaboration with Cincinnati Children's Hospital Medical Center/University of Cincinnati Medical Center Proton Therapy Center announced the achievement of a significant milestone in the path towards clinical trials of FLASH therapy*. The combined research team utilized a Varian ProBeam® proton therapy gantry treatment room in research mode to successfully complete a FLASH delivery to a phantom target. This...This story is related to the following:Radiotherapy Systems |
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news
Study Objectives:Children with craniopharyngioma are at risk for excessive daytime sleepiness (EDS). Multiple Sleep Latency Testing (MSLT) is the gold standard for objective evaluation of EDS; however, it is time and resource intensive. We compared the reliability, sensitivity, and specificity of the modified Epworth Sleepiness Scale (M-ESS) and MSLT in monitoring EDS in children with craniopharyngioma.Methods:Seventy patients (ages 6 to 20 years) with craniopharyngioma completed the M-ESS and were evaluated by polysomnography and MSLT. Evaluations were made after surgery, if performed, and before proton therapy.Results:MS...
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Source Type: research
Condition:   Pediatric Cancer Intervention:   Sponsor:   St. Jude Children's Research Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The Proton Therapy Center operated by Cincinnati Children ’s Hospital and UC Health has hit a significant milestone in researching the use of high doses of proton beams delivered at ultra-high speeds to treat cancer. The advancement in so-called flash therapy, which is delivered in one to three sessions that each last less than one second, is a step tow ard clinical trials. Equipment maker Varian Medical Systems of Palo Alto, Calif., has been researching the value of such ultra-high-dose-rate proton…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Abstract In presence of inter-fractional anatomical changes, clinical benefits are anticipated from image-guided adaptive radiotherapy. Nowadays, cone-beam CT (CBCT) imaging is mostly utilized during pre-treatment imaging for position verification. Due to various artifacts, image quality is typically not sufficient for photon or proton dose calculation, thus demanding accurate CBCT correction, as potentially provided by deep learning techniques. This work aimed at investigating the feasibility of utilizing a cycle-consistent generative adversarial network (cycleGAN) for prostate CBCT correction using unpaired trai...
Source: Physics in Medicine and Biology - Category: Physics Authors: Tags: Phys Med Biol Source Type: research
ConclusionsInstitution of a BP biologic dose constraint may reduce brachial plexopathy risk without compromising target coverage. MCBD plan evaluation provides valuable information to physicians that may assist in making clinical judgments regarding relative priority of target coverage versus normal tissue sparing.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Proton therapy developer Ion Beam Applications (IBA) and Azrieli Centre for...Read more on AuntMinnie.comRelated Reading: IBA takes next step in China deal IBA to install carbon therapy in France IBA posts revenue increase in 1st half of 2019 IBA inks deal to install cyclotron in South Korea IBA takes order from Kan.
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Patient-specific collimators used in proton therapy are activated after use. The aim of this work is to assess the residual activity in brass collimators considering clinical beams, so far studied only for monoenergetic beams, and to develop a model to calculate the activity. Eight brass collimators irradiated with different clinical and monoenergetic beams were included in the study. The collimators were analyzed with gamma spectrometry in the framework of three independent studies carried out at the two French proton therapy sites. Using FLUKA (a fully integrated particle physics Monte Carlo simulation package), simulati...
Source: Health Physics - Category: Radiology Tags: PAPERS Source Type: research
More News: China Health | Medical Devices | Proton Therapy